Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) is positioning itself within the expanding DNA Damage Response (DDR) oncology market through development of ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple DNA repair pathways. According to an editorial from BioMedWire, DDR-targeting therapies generated more than $7 billion in global sales in 2025, while the broader oncology, diagnostics and precision medicine markets are projected to approach $750 billion by 2030.
The company holds exclusive worldwide rights to a portfolio of PNKP inhibitor technologies, including core compounds, delivery systems and synthetic lethality applications intended to support future development across multiple cancer indications. The editorial noted that ONC010 has demonstrated encouraging preclinical results, including extended survival and tumor growth reduction in colorectal cancer models, while the company advances manufacturing, formulation and IND-enabling activities through partnerships with Dalton Pharma Services and Nucro-Technics.
Onco-Innovations also acquired Inka Health Corp., whose SynoGraph causal AI platform is designed to support patient stratification and clinical trial design as the company prepares for anticipated first-in-human studies. The report highlighted continued innovation across the biotechnology sector, citing recent regulatory and clinical milestones reported by Merck & Co. Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE), GSK plc (NYSE: GSK) and Gilead Sciences Inc. (NASDAQ: GILD).
The DDR market's substantial growth underscores the potential impact of Onco-Innovations' approach. By targeting PNKP, an enzyme involved in multiple DNA repair pathways, ONC010 could offer a novel therapeutic strategy for cancers that rely on these repair mechanisms. The nanoparticle encapsulation aims to improve drug delivery and efficacy, potentially addressing limitations of earlier PNKP inhibitors.
Preclinical data showing extended survival and tumor reduction in colorectal cancer models provide a foundation for advancing to human studies. The company's partnerships with contract development and manufacturing organizations Dalton Pharma Services and Nucro-Technics support scale-up and regulatory preparations. Additionally, the acquisition of Inka Health Corp. and its AI platform SynoGraph could enhance patient selection and trial efficiency, which are critical for successful clinical development.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. It has secured an exclusive worldwide license to patented technology that targets solid tumors.
For more information, visit the company's newsroom at https://ibn.fm/ONNVF. The full press release is available at https://ibn.fm/cFCop.
